Biogen Idec/Elan's Tysabri Will Remain Decision Resources' Clinical Gold Standard Through 2018 for the Treatment of Secondary Progressive Multiple Sclerosis

Tuesday, March 2, 2010 Medical PDA News
Email Print This Page Comment bookmark
Font : A-A+

WALTHAM, Mass., March 1 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of secondary progressive multiple sclerosis, Biogen Idec/Elan's Tysabri will remain Decision Resources' proprietary clinical gold standard through 2018. While some drugs in development for multiple sclerosis hold promise, most have less favorable efficacy and/or delivery features compared with Tysabri. Secondary progressive multiple sclerosis is a subpopulation of chronic progressive multiple sclerosis.

The new report entitled Multiple Sclerosis (Chronic Progressive): Amid Few Approved Therapies and Limited Drug Development, Significant Opportunity Awaits New Therapies for Patients with Progressive Forms of MS also finds that a drug approved for secondary progressive multiple sclerosis that reduces long-term disability progression more effectively than Bayer HealthCare's Betaseron would earn 25 - 38 percent patient share in the United States. These high patient shares reflect the unmet need for drugs that have the ability to delay disability progression in multiple sclerosis patients over the long term.

"Surveyed neurologists told us that a drug's effect on long-term disability progression is the attribute that most influences their prescribing decisions in chronic progressive multiple sclerosis," stated Decision Resources Director Bethany Kiernan, Ph.D. "Although Tysabri's robust therapeutic effects have been demonstrated only in relapsing-remitting multiple sclerosis patients, not chronic progressive multiple sclerosis patients, interviewed experts' positive perception of the drug's efficacy extends beyond the relapsing-remitting population. Taken together, these clinical data and the opinions of interviewed thought leaders indicate that Tysabri has advantages over the chronic progressive multiple sclerosis sales leader, Betaseron, on this attribute."

About the Report

Multiple Sclerosis (Chronic Progressive): Amid Few Approved Therapies and Limited Drug Development, Significant Opportunity Awaits New Therapies for Patients with Progressive Forms of MS is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact: Decision Resources Christopher Comfort 781-296-2597

SOURCE Decision Resources

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store